We recently observed in two patients under lenvatinib treatment for advanced HCC an unexpected increase in hemoglobin (Hb) level, leading to a significant erythrocytosis and a subsequent thrombotic risk. The gene discussed is GSTM1; the disease is hepatocellular carcinoma.